Wang and colleagues showed that adding trivalent lanthanide dopant ions at set concentrations tunes NaYF4 upconversion nanocrystals in size (down to 10 nm), crystal phase and emission colour.
As reported in: Wang, Han, Lim et al. (2010). Simultaneous phase and size control of upconversion nanocrystals through lanthanide doping. Nature. doi:10.1038/nature08777
In a phase 3 trial in 143 patients with relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin's lymphoma, yttrium-90 ibritumomab tiuxetan gave an 80% overall response rate versus 56% for rituximab.
Built / tested: 90Y ibritumomab tiuxetan
As reported in: Witzig, Gordon, Cabanillas et al. (2002). Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. doi:10.1200/jco.2002.11.076
Salem and colleagues reported long-term outcomes for 291 patients with hepatocellular carcinoma treated with yttrium-90 microspheres delivered through the liver arteries; patients with Child-Pugh A disease benefited most.
As reported in: Salem, Lewandowski, Mulcahy et al. (2010). Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology. doi:10.1053/j.gastro.2009.09.006